

Appendix I: Tables and Graphs**Table of Contents**

Table 1: Individual concentration of CPA (ng/ml) in the serum of 36 volunteers following a single oral administration of two tablets of Androcur 50 mg.....	2
Table 1a: Continuation.....	3
Table 2: Individual concentration of CPA (ng/ml) in the serum of 36 volunteers following a single oral administration of one tablet of Androcur 100 mg.....	4
Table 2a: Continuation.....	5
Table 3: Individual pharmacokinetic parameters of CPA obtained from 36 male volunteers who received a single oral administration of two tablets of ANDROCUR 50.....	6
Table 4: Individual pharmacokinetic parameters of CPA obtained from 36 male volunteers who received a single oral administration of one tablet of ANDROCUR 100.....	7
Figures 1a - 36a: Individual concentration of CPA in 36 men following the oral administration of two ^{one} tablets of Androcur 100.....	8-43
Figures 1b - 36b: Individual concentration of CPA in 36 men following the oral administration of one ^{two} tablet of Androcur 50.....	44-79

Table 1: Individual concentration of CPA (ng/ml) in the serum of 36 volunteers following a single oral administration of two tablets of Androcur 50 mg.

TIME	1	2	3	4	5	6	7	8	9
[h]									
0	0	0	0	0	0,9	0	0	0	0
0,5	27,8	2,6	248,4	7,9	7,8	111,4	3,3	13,3	34,2
1	99,4	19	410,4	113,9	126,5	288,6	18,5	164,5	133,3
1,5	122,7	29,2	386,9	203,1	232,5	345,4	45,3	417,1	174,6
2	129,6	38,3	375,8	188,4	205	337	161,4	417,7	176,1
3	154,8	87,1	334,8	208,9	162	233,5	163,8	516	184,5
4	132,7	334,4	270,1	174,6	99,8	217,9	177,4	325,7	174,3
6	100,7	228	168,3	178,9	82,7	190	158,7	238,8	141,4
8	93,4	182,5	170,5	138,1		111,9	152	182,4	101,8
12	87,5	136,1	179,1	105,4		84,4	154,3	114	81,9
24	54,7	60,5	65,1	48,8		43,8	75,2	61	40,8
48	29	32,5	43,6	25,5		29,2	56,7	33,4	28,5
72	22	17,5	39,4	20,1		19,1	40,8	22	20,1
96	16,4	11,6	24	13,7		11,8	30,4	16,4	13,7
120	11,3	7,8	16,7	10,5		7,1	23,9	11,7	11,1

TIME	10	11	12	13	14	15	16	17	18
[h]									
0	2,5	0	0	0	0	0	0	0	0
0,5	27,9	26,3	7,2	16	16	96,4	3,6	26,4	47,9
1	74,5	229,3	52,4	226,7	88,2	219,9	10,9	112,6	242,9
1,5	123,1	208,6	69,5	339,8	140	242,3	75,3	136,8	322,7
2	167,1	206,8	95,6	349,6	150	256,8	92,1	140,7	331,2
3	151	183,2	149,2	297,4	84,3	287	434	202,1	390
4	107,2	143,3	126,8	138,3	69,7	176,5	353,4	162,6	335,5
6	73,5	151,5	98,5	83,4	42,5	169,2	157,8	123,1	331,3
8	79,1	124,5	94,4	85,3	107,8	138,6	113,2	109,9	294,7
12	80,8	90,5	102,5	103,7	57	89,2	146,6	144	196,2
24	59,5	41,6	100,1	65,3	96,2	59,6	54,6	96,3	89,6
48	36,1	26,1	46,4	40,4	52,4	31,4	32	39,5	52,2
72	42,7	16	27,6	29,7	35,7	20,2	24	30,3	32
96	24,8	16,3	22,7	22,4	29,5	13,8	14,9	18,5	23,5
120	26,7	19,4	17	18,2	19,9	10,1	11,8	15,6	17,9

Table 1a: Continuation

TIME	19	20	21	22	23	24	25	26	27
[h]									
0	0	0	0	0	0	0	0	0	0
0,5	2,1	3	7,5	9,8	82,3	1,8	7,1	10	58,6
1	58,4	18,2	74,1	25,5	262,8	43	58,6	31	178,6
1,5	170,7	42	154,3	76,4	338,3	65,6	106,3	74,9	179,8
2	211,5	68,8	181,2	91,7	392,1	91,4	221,2	197,6	179
3	330,1	192,5	163,2	382,5	172,7	339,9	449,8	312,9	168,1
4	238,8	238,5	123,5	105,8	409,4	194,7	276,2	221	143,7
6	157,6	125,3	116,2	51	242,8	143,9	245,6	141,8	119,8
8	110,5	124	117,5	38,1	191,2	104,1	204,7	144,2	104
12	89,9	101,9	152,2	32,8	107	84,4	158,7	134,9	105
24	50,2	76,1	138,7	18,1	69	51,8	86,4	79,6	104,8
48	20,7	37,6	85,2	10,6	24,3	28,3	47,7	35,2	50,7
72	12,3	23,1	54,6	7,7	14,3	21	34,8	28,1	32,5
96	7,3	18,8	47,2	6,3	6,4	16,1	29,4	20,3	21,4
120	4,5	15,3	40,3	2,6	4,8	13,9	23,4	16,5	16,8

TIME	28	29	30	31	32	33	34	35	36	MEAN	± SD
[h]											
0	3,5	0	0	0	0	0	0	1	0	0,2	0,7
0,5	159,5	62,6	27,8	7,7	17,2	30	12,1	126,4	6,8	37,7	52,8
1	418,5	273,4	95,4	97,1	113,3	103,7	88,2	294,5	63	136,9	108,1
1,5	471,5	245,4	244,3	118,1	139,4	113,5	128,5	233,8	87,9	183,5	114,2
2	465,1	265,3	342,7	124,6	127,5	119,1	137,1	240,6	113,2	205,2	107,8
3	282,4	233,3	127,8	133,6	191,3	350,5	150,4	344,5	222,9	243,7	107,9
4	270,7	220	326,5	144,1	154,8	97,8	131,1	237,7	232,9	202,4	84,9
6	213,9	199,8	177,5	196,5	138,2	65,5	123,2	176,5	179,6	153,7	61,3
8	163,7	138,1	145,8	164,6	97,1	85,7	131,8	162,9	149,7	133,0	45,7
12	149	123,8	100,4	130,5	66,9	72,4	107,8	103,4	111,2	111,0	34,9
24	98,4	63,7	65,2	81	74,4	36,5	66,1	52,4	45,2	67,7	23,7
48	41,6	33,2	33,1	59,8	30	16,8	36,5	41	24,1	36,9	13,9
72	30,5	25,5	21,3	40,4	21,4	10,8	24,6	26,5	16,1	25,8	10,1
96	28,7	14	12,6	31,2	15,4	10,3	18	23	11,3	18,9	8,4
120	22,7	10,6	8,5	24,9	10	5,8	9,9	17,3	10,3	14,7	7,6

Values below the lower limit of quantification (0.5 ng/ml) were set to zero.

- no sample

Table 2: Individual concentration of CPA (ng/ml) in the serum of 36 volunteers following a single oral administration of one tablet of Androcur 100 mg

TIME [h]	1	2	3	4	5	6	7	8	9
0	0	0	0	0	0	0	0	0	0
0,5	35,8	5,1	36,4	0	2	170,2	9,9	23,2	0,7
1	63,5	37,5	288,2	9,5	11,4	233	46,8	192,4	14,8
1,5	74,7	71,7	308,4	22,8	50,7	266,6	118,4	247,8	56,2
2	76,6	84,6	258	41,7	100,9	284,3	139,1	303,7	129,7
3	97,1	92,5	192,5	256,4	150,1	216,1	190,5	464,8	174,5
4	94,1	70	157,3	280,8	135,9	214,9	182,5	334,9	160,8
6	67,7	49	110,5	193,4	101,5	160,2	127,4	265,4	100
8	78,8	59,9	136,2	166,5	91,5	128,3	140,7	193,8	102
12	67,6	90,9	144,6	122,8	109,2	98,9	133,8	126,2	83,4
24	59,3	77,8	68,4	44,4	71,2	59,2	67,2	-	51,5
48	27,3	26,4	42,6	25,6	33,7	35	34,3	34,3	30,7
72	22,7	17,4	29,5	18	23,8	21,6	29	24,3	22,2
96	19,9	12	23,3	13,3	18,1	13,6	23,4	17,7	17,3
120	14,6	9,2	15,6	11,6	13,3	9,2	16,2	14,7	11,4

TIME [h]	10	11	12	13	14	15	16	17	18
0	0,4	*	0	0	0	0	0	0	0
0,5	120,4	1,9	12,8	17,6	19,1	28,5	229,7	7,8	27
1	305,3	7,6	101,4	52,4	144,7	68,2	620,7	46,3	122,8
1,5	274,3	25,1	281,7	266,5	90,4	82,6	531,8	67,3	128
2	269,7	42,7	325,9	256,7	106,5	117,1	483,9	91,3	156,9
3	211,3	146,2	326,6	194,4	100,1	175,3	427,4	140	141,2
4	120,3	154,7	252,5	132,6	77,1	132,5	266,5	180,3	187,6
6	94,9	143,4	140	99,4	54,3	111,2	168,3	143,6	230
8	90,2	143,2	124,1	97,8	53	96	139	189	213,4
12	108,4	129,9	108,1	94,3	133,5	91,9	89,7	159,7	168,7
24	85,3	47,6	73	72,8	66,1	67,6	55,6	62,6	92,2
48	36,8	21,3	39,8	31,1	33	26,7	34,7	37,4	44,8
72	31,4	19,8	38,5	24	12	16,2	23,1	25,9	29,2
96	25,8	12,2	28,2	16,9	11,6	13,3	19	17,5	25,6
120	26,2	11,1	14,2	12,5	10,6	9,8	15	14	16,6

* no plausible value (was set to zero)

Table 2a: Continuation

TIME	19	20	21	22	23	24	25	26	27
[h]									
0	0	0	0	0	0	0	0	0	0
0,5	2,1	3,5	2,6	7,7	0,9	2,9	19,4	24,9	16,5
1	88,9	20,2	12,8	54,5	25	68,1	206,3	228,2	64,6
1,5	143,7	26	43,6	63,5	109,3	75,5	250,8	201,2	98,9
2	181,7	65,7	72,8	71,1	150,9	80,7	324	185,9	209,2
3	159,3	187,7	106,8	65,1	335,1	118,4	180,2	184,6	208,1
4	181,8	165,1	187,8	37,7	328,3	111,3	207,7	115,2	220,6
6	131,4	79,6	166,8	29,1	258,5	112,9	149,8	102	132,7
8	131,8	81,7	147	27,3	191,5	96,2	148,5	103,7	93,9
12	105,8	77,5	188,6	20,2	175,3	86,4	121,3	133,5	93,5
24	64,7	54,7	149,2	12	72,3	68	74,6	92,7	89,4
48	31,2	28,8	90,1	8,1	30,8	41,7	39,8	37,1	43,1
72	16,3	21,4	68,7	5,3	17,6	30,7	28,3	26,3	23,4
96	10,3	17,6	52,4	4,3	13,1	19,9	20,1	19,9	16,8
120	6,9	9,9	37,7	3,7	6,6	15,8	17,7	16,3	11,8

TIME	28	29	30	31	32	33	34	35	36	MEAN	± SD
[h]											
0	0	0	0	0,6	0	0	0	0	0,3	0	0,1
0,5	1,6	40,1	3	4,2	7,3	8,8	2,6	0,6	21,6	25,5	48,4
1	8,4	120,8	48,4	18,5	41,8	52,7	16	18,8	106,5	99,1	121
1,5	10,6	161,5	135,7	21,2	93,5	63,8	117	108,6	134	134	109,1
2	15,2	185,8	207,6	18,6	179,1	84	132,6	128,1	140,7	158,4	102,5
3	260,5	195	363,2	122,3	294,8	89,6	259,9	214,7	240,2	201,7	93,5
4	415,5	181,6	279	280,6	271,5	88,2	137,3	233,2	211,1	188,6	82,6
6	435,8	138,2	194,4	186,6	218,6	82	104,4	157,6	120,6	143,4	74,5
8	361,7	105,9	199,5	162,9	186,6	91,2	86,1	156,8	113,8	131,4	59,5
12	190	71,5	139,6	122,3	100,7	98,7	76,6	145,5	89,7	113,8	36,1
24	90,3	52	76,4	82,6	53,2	52,5	72,7	90,9	52,3	69,2	21,6
48	48,2	29,2	34,8	56,5	27,4	22	40,3	43	22,9	35,3	12,9
72	44,8	13,3	19,2	42,2	21,4	10,7	26,9	26	19	24,7	11,1
96	28,8	13,6	12,6	31,1	14,4	7,5	17,9	19,2	12	18,3	8,3
120	28,9	10	6,8	26	14,7	5,9	11,2	14,8	8,7	13,9	6,8

Values below the lower limit of quantification (0.5 ng/ml) were set to zero.

- no sample

Table 3: Individual pharmacokinetic parameters of CPA obtained from 36 male volunteers who received a single oral administration of two tablets of ANDROCUR 50

- several samples missing

subject	C _{max} [ng/ml]	t _{max} [h]	AUC(0-24h) [ng·ml ⁻¹ ·h]	AUC(0-120h) [ng·ml ⁻¹ ·h]	AUC [ng·ml ⁻¹ ·h]	t _½ [h]	MRT [h]	CL [ml/min/kg]	V _Z [l]
1	154.8	3	2085.8	4495.4	5081.3	35.9	36.2	3.7	1020
2	334.4	4	3098.1	5396.1	5761.2	32.4	28.6	3.9	812
3	410.4	1	4216.2	7765.8	8973.7	50.1	32.6	2.7	806
4	203.1	1.5	2676.7	4811.5	5493.6	45	31.1	3.1	1180
5	-	-	-	-	-	-	-	-	-
6	345.4	1.5	2839.5	4892.7	5267.6	36.6	28.4	4.2	1000
7	177.4	4	3043.7	7302.5	9269.6	57.1	40.4	2.5	888
8	516	3	3918.1	6513.7	7213.3	41.4	27.7	3	829
9	184.5	3	2237.3	4355.3	5153.8	49.9	33.7	4.3	1400
10	167.1	2	1938.2	5459	8121.3	69.1	45.6	2.5	1230
11	229.3	1	2435.5	4569.1	6901.2	83.3	34.3	2.3	1740
12	149.2	3	2346.5	6072.5	7030	39	38.8	3.1	801
13	349.6	2	2702.4	5924.4	7313.3	52.9	37.1	3	1040
14	150	2	1865.1	6080.7	7362.5	44.6	44.4	4.1	875
15	287	3	2849.1	5255.1	5761.5	34.8	30.4	3.4	870
16	434	3	3233.7	5732.1	6471.8	43.5	30.6	3.4	969
17	202.1	3	2995.1	6457.1	7308.2	37.8	34.8	3	747
18	390	3	5102.3	8977.1	10046	41.4	29.9	2.3	594
19	330.1	3	2629.6	4253.2	4420.1	25.7	25	5.3	839
20	238.5	4	2527.9	5532.7	6332.5	36.2	35.8	3.2	826
21	181.2	2	3237	9873	12930.1	52.6	44.5	1.9	587
22	382.5	3	1253.1	2091.9	2233.7	37.8	27.9	10.7	2440
23	392.1	2	3751.8	5717.4	5880	23.5	22	4.5	576
24	339.9	3	2341.8	4699.8	5563.4	43.1	34.7	2.7	1120
25	449.8	3	4009.3	8012.5	9826.2	53.7	35	2.2	789
26	312.9	3	3123.6	6283.2	7807.3	64	34.2	3.2	1180
27	179.9	1.5	2746.8	6716.4	7607.7	36.8	37.1	3.3	697
28	471.5	1.5	4264.2	8136.6	9785.2	50.3	32.8	2.2	742
29	273.4	1	3239.5	5875.9	6340.1	30.4	30.2	3.5	691
30	342.7	2	3045.1	5537.5	5914.9	30.8	29.4	3.7	750
31	196.5	6	2971.5	7395.9	9381.4	55.3	40.8	2.2	850
32	191.3	3	2203.4	4819.4	5352.3	36.9	34.4	3.5	996
33	350.5	3	1896.4	3313.6	3566	30.2	29.5	4.8	1220
34	150.4	3	2465.1	5275.5	5729.7	31.8	35.1	4	801
35	294.5	1	3192.4	6200.8	7686.6	59.5	34.3	2.9	1120
36	232.9	4	2705.1	4607.1	5272.5	44.8	29.2	3.9	1230
mean	285.6	2.6	2891.1	5840.1	6861.7	43.9	33.6	3.5	978.7
± S.D.	105.2	1.1	780.2	1553.2	2078.8	12.8	5.4	1.5	354.0

For abbreviations see footnote on page 7

Table 4: Individual pharmacokinetic parameters of CPA obtained from 36 male volunteers who received a single oral administration of one tablet of ANDROCUR 100

- 24 h value missing

subject	C _{max} [ng/ml]	t _{max} [h]	AUC(0-24h) [ng·ml ⁻¹ ·h]	AUC(0-120h) [ng·ml ⁻¹ ·h]	AUC [ng·ml ⁻¹ ·h]	t _{1/2} [h]	MRT [h]	CL [ml/min/kg]	V _z [l]
1	97.1	3	1651.1	4215.5	5156.4	44.7	41.1	3.6	1250
2	92.5	3	1789	4172.2	4585.5	31.1	35.1	4.9	980
3	308.4	1.5	3135.3	6432.9	7484.7	46.7	35.2	3.3	901
4	280.8	4	2860.1	4897.7	5731.4	49.8	30.2	3	1250
5	150.1	3	2240	5068.4	5771.4	36.6	36.9	3.5	916
6	284.3	2	2938.3	5443.9	5916.8	35.6	30.3	3.7	869
7	190.5	3	2806.6	5888.2	7092.8	51.5	36.6	3.3	1050
8	464.8	3	-	7276.2	8510.3	58.2	26.9	2.6	986
9	174.5	3	2031	4470.6	5137.2	40.5	37.1	4.3	1140
10	305.3	1	2783.5	6377.5	8300.9	50.9	38.7	2.4	884
11	154.7	4	2468.8	4452.4	5220.3	48	32	3.1	1330
12	326.6	3	3102.8	6705.2	7646.9	46	36.9	2.8	867
13	266.5	1.5	2437.5	5189.1	6161.5	53.9	34.7	3.6	1260
14	144.7	1	2154.9	4433.7	4974.3	35.3	32.7	6.1	1030
15	175.3	3	2202.7	4480.3	4947.1	33	32.8	4	963
16	620.7	1	3689.7	6380.1	7497.3	51.6	29.4	2.9	993
17	180.3	4	3047	5905.4	6800.3	44.3	33.6	3.3	940
18	156.9	2	3682.2	7378.2	8377	41.7	34	2.8	718
19	181.8	2	2578.4	4824.8	5086.1	26.3	29.6	4.6	745
20	187.7	3	1862	4264.4	4806.7	38	37.7	4.2	1140
21	187.8	4	3651.2	10962.8	13547.4	47.5	44.4	1.8	506
22	71.1	2	611.5	1224.7	1522.1	55.7	34.7	15.6	5280
23	335.1	3	3936	6358.8	6639.6	29.5	25.9	4	641
24	118.4	3	2032.7	5253.5	6218.5	42.3	40.4	2.4	982
25	324	2	3116.1	6340.5	7533.7	46.7	34.4	2.8	895
26	228.2	1	2863.3	6170.5	7595	60.6	35	3.3	1150
27	209.2	2	2617.4	5831	6398.3	33.3	34.2	3.9	751
28	435.8	6	4924.4	9279	11760.3	59.5	34	1.9	730
29	195	3	2246.1	4336.5	4874.9	37.3	31.8	4.6	1100
30	363.2	3	3593.5	6190.3	6426.9	24.1	27.3	3.4	541
31	280.6	4	2915.2	7333.6	9211.6	50.1	41.3	2.3	784
32	294.8	3	3029.5	5361.1	6458.2	51.7	30.9	2.9	1160
33	89.6	3	1889.8	3555.4	3781.8	26.6	29.8	4.5	1010
34	259.9	3	2149.2	5197.2	5780.1	36.4	37.3	3.9	909
35	233.2	4	3219.6	6604.8	7405.4	37.5	33.5	3	730
36	240.2	3	2407.2	4432.8	4926	39.3	30.9	4.1	1150
mean	239.2	2.8	2704.7	5630.3	6535.7	42.8	34.1	3.8	1070.3
± S.D.	114.2	1.1	792.6	1660.8	2140.3	9.7	4.2	2.2	749.1

For abbreviations see footnote¹

¹C_{max} = maximum concentration of drug

t_{max} = time to reach C_{max}

AUC (0 - 24h) = area under the serum level-time curve from 0 to 24 h

AUC (0 - 120 h) = area under the serum level-time curve from 0 to 120 h

AUC = area under the serum level-time curve extrapolated to infinity

t_{1/2} = terminal half life

MRT = mean residence time

Cl = total serum clearance

V_z = volume of distribution





Fig. 1a: Concentration of CPA in the serum of subject 1 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 2a: Concentration of CPA in the serum of subject 2 following oral administration of one tablet of Androcur 100 mg.
 Top: linear presentation; bottom: semilogarithmic presentation




Fig. 3a: Concentration of CPA in the serum of subject 3 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 4a: Concentration of CPA in the serum of subject 4 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 5a: Concentration of CPA in the serum of subject 5 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 6a: Concentration of CPA in the serum of subject 6 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 7a: Concentration of CPA in the serum of subject 7 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 8a: Concentration of CPA in the serum of subject 8 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 9a: Concentration of CPA in the serum of subject 9 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 10a: Concentration of CPA in the serum of subject 10 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 11a: Concentration of CPA in the serum of subject 11 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 12a: Concentration of CPA in the serum of subject 12 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 13a: Concentration of CPA in the serum of subject 13 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 14a: Concentration of CPA in the serum of subject 14 following oral administration of one tablet of Androcur 100 mg.

Top: linear presentation; bottom: semilogarithmic presentation




Fig. 15a: Concentration of CPA in the serum of subject 15 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 16a: Concentration of CPA in the serum of subject 16 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 17a: Concentration of CPA in the serum of subject 17 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 18a: Concentration of CPA in the serum of subject 18 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 19a: Concentration of CPA in the serum of subject 19 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 20a: Concentration of CPA in the serum of subject 20 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig.21a: Concentration of CPA in the serum of subject 21 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 22a: Concentration of CPA in the serum of subject 22 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 23a: Concentration of CPA in the serum of subject 23 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 24a: Concentration of CPA in the serum of subject 24 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 25a: Concentration of CPA in the serum of subject 25 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 26a: Concentration of CPA in the serum of subject 26 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation





Fig. 27a: Concentration of CPA in the serum of subject 27 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 28a: Concentration of CPA in the serum of subject 28 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation




Fig. 29a: Concentration of CPA in the serum of subject 29 following oral administration of one tablet of Androcur 100 mg.
Top: linear presentation; bottom: semilogarithmic presentation